Newman Yeilding

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

Medicine, Dermatology, Immunology +15

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

Medicine, Dermatology, Immunology +15

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof et al. · New England Journal of Medicine · 2010 · 851 citations

Medicine, Dermatology, Pharmacotherapy +13

A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis

Gerald G. Krueger, Richard G. Langley, Craig L. Leonardi et al. · New England Journal of Medicine · 2007 · 785 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Tumor Vessel Development and Maturation Impose Limits on the Effectiveness of Anti-Vascular Therapy

Michael S. Gee, William N. Procopio, Sosina Makonnen et al. · American Journal Of Pathology · 2003 · 243 citations · Full text

Medicine, Cancer Biology, Oncology +16